You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.
Researchers from South Korea used 10x Genomics' scRNA-seq platform to also find type I IFN-driven inflammatory features in patients with severe influenza.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
Single-cell RNA sequencing uncovered interactions between colorectal cancer alterations and corresponding immune cell and stromal features.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.